22-hydroxydocosanoic acid, sodium salt

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 22-hydroxydocosanoic acid, sodium salt
• 英文别名: Sodium;22-hydroxydocosanoate
• 化学式: C₂₂H₄₃O₃*Na
• 分子量: 378.571
• InChiKey: KJJNJFYLDHWBOL-UHFFFAOYSA-M

计算性质

• 辛醇/水分配系数(LogP)：
  2.53
• 重原子数：
  26
• 可旋转键数：
  21
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.95
• 拓扑面积：
  60.4
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  18-hydroxyoctadec-9-enoic acid, sodium salt 、 9,10-epoxy-18-hydroxyoctadecanoic acid, sodium salt 、 threo-9,10,18-trihydroxyoctadecanoic acid, sodium salt 、 22-hydroxydocosanoic acid, sodium salt 、 sodium betulinate 在 盐酸 作用下， 以 水 为溶剂， 生成 白桦脂酸 、 9,10-epoxy-18-hydroxy-octadecanoic acid 、 18-hydroxyoctadec-9-enoic acid 、 Phloionol-saeure 、 22-羟基二十二烷酸
  参考文献：
  名称：

  WO2007/121482

  摘要：

  公开号：

文献信息

• Crystalline polyolefin composition
  申请人：Chisso Corporation

  公开号：EP0416321A1

  公开（公告）日：1991-03-13

  A crystalline polyolefin composition which provides molded articles having improved stiffness characteristics is disclosed, comprising 100 parts by weight of a crystalline polyolefin, (A) from 0.001 to 1 part by weight of a fluorophosphite compound represented by formula (I): wherein R represents an alkylidene group having from 1 to 4 carbon atoms or a sulfur atom; Ar1 and Ar2, which may be the same or different, each represents an alkylarylene group or a cycloalkylarylene group; and n represents 0 or 1, and (B) from 0.001 to 1 part by weight of at least one compound selected from the group consisting of (1) an aliphatic monocarboxylic acid salt with lithium or sodium, (2) a dithiocarbamic acid salt with lithium, sodium or potassium, (3) a 2-mercaptobenzothiazole salt with lithium, sodium or potassium, (4) a 2-mercaptobenzimidazole salt with lithium, sodium or potassium and (5) a benzotriazole salt with lithium, sodium or potassium. A crystalline polyolefin composition which provides molded articles having improved stiffness charateristics is also disclosed, comprising 100 parts by weight of a crystalline polyolefin, (A) from 0.001 to 1 part by weight of a fluorophosphite compound represented by formula (I) shown above, (B ) from 0.001 to 1 part by weight of at least one compound selected from the group consisting of (1) an aliphatic monocarboxylic acid salt with potassium, strontium or barium, (2) a hydroxy-higher fatty acid salt with potassium, strontium or barium, (3) an aliphatic polycarboxylic acid salt with lithium, sodium, potassium, strontium or barium, (4) a salt of an aliphatic hydroxy acid having form 2 to 6 carbon atoms with lithium, sodium, potassium, magnesium, strontium or barium, (5) an aromatic carboxylic acid salt with lithium, sodium, strontium, barium or aluminum, (6) a glutamic acid salt with lithium, sodium, potassium, strontium or barium, (7) an aliphatic phosphoric acid salt with sodium, potassium, calcium, strontium or barium, (8) a lithium, sodium, potassium or barium salt of a cyclic phosphorus compound represented by formula (II): wherein Ar3 and Ar4, which may be the same or different, each represents an arylene group, an alkylarylene group, a cycloalkylarylene group, an arylarylene group or an aralkylarylene group; M represents lithium, sodium, potassium or barium; and m represents an atomic valence of M, (9) magnesium or aluminum hydroxide, (10) magnesium oxide, (11) magnesium or calcium carbonate and (12) hydrotalcite, and (C) from 0.01 to 1 part by weight of an aliphatic amine.

  本发明公开了一种结晶聚烯烃组合物，该组合物可提供具有改进的刚度特性的模塑制品，该组合物包括按重量计100份的结晶聚烯烃、(A)按重量计0.001至1份的由式(I)代表的亚磷酸氟化合物： 其中 R 代表具有 1 至 4 个碳原子的亚烷基或硫原子；Ar1 和 Ar2 可以相同或不同，各自代表烷基芳基或环烷基芳基；n 代表 0 或 1，以及 (B) 0.(1) 锂或钠的脂肪族一羧酸盐，(2) 锂、钠或钾的二硫代氨基甲酸盐、(3) 锂、钠或钾的 2-巯基苯并噻唑盐， (4) 锂、钠或钾的 2-巯基苯并咪唑盐， (5) 锂、钠或钾的苯并三唑盐。 本发明还公开了一种结晶聚烯烃组合物，该组合物可提供具有改进的刚度特性的模塑制品，其成分包括 100 份（重量）结晶聚烯烃、(A) 0.001 至 1 份（重量）由上文式(I)代表的亚磷酸氟化合物、(B ) 0.(1)钾、锶或钡的脂肪族一羧酸盐；(2)钾、锶或钡的羟基高级脂肪酸盐；(3)锂、钠、钾、锶或钡的脂肪族多羧酸盐；(4)锂、钠、钾、镁、锶或钡的具有 2 至 6 个碳原子的脂肪族羟基酸盐、(5) 锂、钠、锶、钡或铝的芳香族羧酸盐； (6) 锂、钠、钾、锶或钡的谷氨酸盐、(7) 含有钠、钾、钙、锶或钡的脂肪族磷酸盐， (8) 由式（II）代表的环磷化合物的锂、钠、钾或钡盐： 其中 Ar3 和 Ar4 可以相同或不同，各自代表芳基、烷芳基、环烷芳基、芳基芳基或芳基芳基；M 代表锂、钠、钾或钡；m 代表 M 的原子价，(9) 氢氧化镁或铝，(10) 氧化镁，(11) 碳酸镁或碳酸钙和 (12) 水滑石，以及 (C) 0.01至1份重量的脂肪族胺。
• Anti-fungal formulation of triterpene and essential oil
  申请人：Carlson M. Robert

  公开号：US20050014730A1

  公开（公告）日：2005-01-20

  The present invention provides for pharmaceutical compositions that includes a triterpene (e.g., betulin) and an essential oil (Vicks® Vapor Rub). The present invention also provides for a cosmetic formulation that includes a triterpene (e.g., betulin) and an essential oil (Vicks® Vapor Rub). The present invention also provides a method of treating a fungal infection that includes administering (e.g., topically applying) an effective amount of the pharmaceutical composition to the tissue afflicted with the fungal infection, or the tissue at risk of being afflicted with the fungal infection.

  本发明提供的药物组合物包括一种三萜（如白桦脂）和一种精油（Vicks® Vapor Rub）。本发明还提供了一种化妆品配方，其中包括一种三萜（如白桦脂素）和一种精油（Vicks® Vapor Rub）。本发明还提供了一种治疗真菌感染的方法，该方法包括将有效量的药物组合物施用于（如局部施用）受真菌感染的组织或有受真菌感染风险的组织。
• Compositions that include a triterpene and a carrier
  申请人：Krasutsky A. Pavel

  公开号：US20060003948A1

  公开（公告）日：2006-01-05

  The present invention provides for compositions that includes a triterpene (e.g., betulin) and a carrier (e.g., lanolin). The compositions are useful for skin care (e.g., as cosmetic formulations), and as therapeutic formulations, e.g., for treating topical fungal infections.

  本发明提供了包括三萜（如白桦脂）和载体（如羊毛脂）的组合物。这些组合物可用于皮肤护理（如化妆品配方）和治疗配方，如治疗局部真菌感染。
• US5063264A
  申请人：——

  公开号：US5063264A

  公开（公告）日：1991-11-05
• [EN] ANTI-FUNGAL FORMULATION OF TRITERPENE AND ESSENTIAL OIL<br/>[FR] PREPARATION ANTIFONGIQUE A BASE DE TRITERPENE ET D'HUILE ESSENTIELLE
  申请人：UNIV MINNESOTA

  公开号：WO2004089357A2

  公开（公告）日：2004-10-21

  The present invention provides for pharmaceutical compositions that includes a triterpene (e.g., betulin) and an essential oil (Vicks® Vapor Rub). The present invention also provides for a cosmetic formulation that includes a triterpene (e.g., betulin) and an essential oil (Vicks® Vapor Rub). The present invention also provides a method of treating a fungal infection that includes administering (e.g., topically applying) an effective amount of the pharmaceutical composition to the tissue afflicted with the fungal infection, or the tissue at risk of being afflicted with the fungal infection.